Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Lundin, J
Kimby, E
Bjorkholm, M
Celsing, F
Hale, G
Hjalmar, V
Merup, M
Petrescu, A
Tullgren, O
Waldmann, H
Mellstedt, H
Osterborg, A
机构：
[1] Karolinska Inst, S-10401 Stockholm, Sweden
[2] Therapeut Antibody Ctr, Oxford, England
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：772A / 772A
页数：1
相关论文
共 50 条
  • [41] Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving Alemtuzumab (Campath-1H) therapy.
    Dearden, CE
    Matutes, E
    Cazin, B
    Ireland, R
    Parreira, A
    Lakhani, A
    Catovsky, D
    BLOOD, 2003, 102 (11) : 644A - 644A
  • [42] In-vitro treatment of chronic lymphocytic leukemia (CLL) cells with fludarabine, etoposide and alemtuzumab (campath-1H) reveals different rates and mechanisms of cell death.
    Winkler, D
    Schneider, C
    Nitsch, D
    Habermann, A
    Doehner, H
    Stilgenbauer, S
    BLOOD, 2005, 106 (11) : 597A - 597A
  • [43] Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia: High frequency of cytomegalovirus disease and delayed neutropenia.
    Lin, TS
    Flinn, IW
    Lucas, MS
    Sickler, J
    Moran, ME
    Porcu, P
    Lucas, DM
    Grever, MR
    Byrd, JC
    BLOOD, 2002, 100 (11) : 802A - 803A
  • [44] An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine I.
    Paul, Harminder
    Snitzler, Susi
    Le, Lisa W.
    Wei, Ellen Nong
    Lau, Anthea
    Johnston, James B.
    Gibson, Spencer B.
    Queau, Michelle L.
    Trudel, Suzanne
    BLOOD, 2015, 126 (23)
  • [45] Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
    Soumerai, Jacob D.
    Davids, Matthew S.
    Werner, Lillian
    Fisher, David C.
    Armand, Philippe
    Amrein, Philip C.
    Neuberg, Donna
    Hochberg, Ephraim P.
    Brown, Jennifer R.
    Abramson, Jeremy S.
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2931 - 2938
  • [46] Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia
    Kennedy, B
    Rawstron, A
    Carter, C
    Ryan, M
    Speed, K
    Lucas, G
    Hillmen, P
    BLOOD, 2002, 99 (06) : 2245 - 2247
  • [47] Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG)
    Stilgenbauer, S
    Kröber, A
    Winkler, D
    Kienle, D
    Busch, R
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
  • [48] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [49] Correlation between Campath-1H and response to therapy in patients with chronic lymphocytic leukemia treated for minimal residual disease.
    Albitar, M
    Manshouri, T
    Giles, F
    Kantarjian, HM
    Keating, MJ
    O'Brien, S
    BLOOD, 2002, 100 (11) : 804A - 804A
  • [50] Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia
    Nabhan, C
    Rosen, ST
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 75 - 80
12345